Search Results for "Influenza vaccine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Influenza vaccine. Results 1 to 10 of 24 total matches.
Influenza Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024 (Issue 1711)
influenza
vaccines improved humoral and cell-mediated
immune responses and reduced influenza-related ...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season are
listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50 doi:10.58347/tml.2024.1711a | Show Introduction Hide Introduction
In Brief: FluMist Influenza Vaccine for Self-Administration
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
In Brief: FluMist Influenza Vaccine for Self-Administration ...
FluMist (AstraZeneca), the live-attenuated intranasal
influenza vaccine that has been available for
years for administration by a healthcare provider
in nonpregnant persons 2-49 years old, has now
been approved by the FDA for self- or caregiver-administration.
It is expected to be available for such
use during the 2025-2026 influenza season. FluMist
is only available through a healthcare provider
this season. It will continue to be available for
administration by a healthcare provider in the future
Med Lett Drugs Ther. 2024 Oct 28;66(1714):174-5 doi:10.58347/tml.2024.1714c | Show Introduction Hide Introduction
Antiviral Drugs for Seasonal Influenza for 2024-2025
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
TREATMENT ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8 doi:10.58347/tml.2024.1717a | Show Introduction Hide Introduction
Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
to serotype 15C due to a similar molecular structure. influenza vaccine. Immune responses elicited when ...
The FDA has licensed Capvaxive (PCV21; Merck),
a 21-valent pneumococcal conjugate vaccine, for
prevention of invasive pneumococcal disease (IPD)
and pneumococcal pneumonia in adults. Four other
pneumococcal vaccines are currently available in the
US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and
Prevnar 13 (PCV13) are conjugate vaccines licensed
for use in persons ≥6 weeks old, and Pneumovax 23
(PPSV23) is a pneumococcal polysaccharide vaccine
licensed for use in persons ≥2 years old (see Table 1).
Med Lett Drugs Ther. 2024 Oct 14;66(1713):161-3 doi:10.58347/tml.2024.1713a | Show Introduction Hide Introduction
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
at increased risk of influenza
complications (see Table 1) who have not received an
influenza vaccine ...
The oral polymerase acidic endonuclease inhibitor
baloxavir marboxil (Xofluza — Genentech) is now FDAapproved
for post-exposure prophylaxis of influenza
in patients ≥12 years old. Baloxavir was approved for
treatment of acute uncomplicated influenza in patients
≥12 years old in 2018.1 Two neuraminidase inhibitors
are FDA-approved for prophylaxis of influenza:
oseltamivir (Tamiflu, and generics) in patients ≥1 year
old, and zanamivir (Relenza) in patients ≥5 years old.2
Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved
for pre-exposure prophylaxis of...
In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
or bacterial infection.
Administration of some COVID-19 and seasonal
influenza vaccines has been associated ...
The FDA has required a new warning in the labels of the
recombinant respiratory syncytial virus (RSV) vaccines
Arexvy (GSK) and Abrysvo (Pfizer) about an increased
risk of Guillain-Barré syndrome (GBS) within 42 days
of administration of either vaccine. Both vaccines
are FDA-approved to prevent lower respiratory tract
disease (LRTD) caused by RSV in adults.Abrysvo is
also approved for use in pregnant women at 32-36
weeks' gestation to prevent RSV-associated LRTD in
their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):31-2 doi:10.58347/tml.2025.1722d | Show Introduction Hide Introduction
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
of certain vaccines in adults
residing in the US.1 Routine childhood immunization
has reduced the overall ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only) ...
A reader of our article on the 2024-2025 formulations of
the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) asked us
to provide more information on the data that supported
their licensure.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e168 doi:10.58347/tml.2024.1713h | Show Introduction Hide Introduction
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
: The CDC Advisory Committee on Immunization
Practices (ACIP) recommends use of either vaccine in adults ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
childhood immunization
has resulted in a 90% reduction in vaccine-type
invasive pneumococcal disease ...
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes of
pneumococcus, and Vaxneuvance (PCV15; Merck),
which contains antigens from 15 serotypes. Two
other pneumococcal vaccines are available in the
US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate
vaccine licensed for use in persons ≥6 weeks old,
and Pneumovax 23 (PPSV23; Merck), a 23-valent
pneumococcal polysaccharide vaccine licensed for
use in persons ≥2 years...